Ovarian Cancer Clinical Trials

Showing 701-720 of 1,019 trials

Non-coding RNA in the Exosome of the Epithelia Ovarian Cancer

NCT03738319

This study aims to analyze the expression of micro-RNA (miRNA) and long non-coding RNA (lncRNA) by next-generation sequencing in patients with high grade serous ovarian cancer (HGSOC) and benign gynecologic diseases. The candidate miRNA/lncRNA will be validated as biomarker for the detection and prognosis of HGSOC.

High Grade Serous CarcinomaOvarian CancerExosomes+2 more

Lei Li160 participantsStarted Nov 2018

Beijing, Beijing Municipality, China

TERMINATEDPhase 1

Intraperitoneal tgDCC-E1 and Intravenous Paclitaxel in Women With Platinum-Resistant Ovarian Cancer

NCT00102622

The goal of this clinical research study is to find the highest safe dose of intraperitoneal tgDCC-E1A that can be given in combination with paclitaxel as a treatment for patients with recurrent, platinum-resistant ovarian cancer. How the cancer responds to this treatment will also be studied. Researchers will also ask the patients if they will allow additional tumor samples to be collected and extra blood samples to be drawn. These samples will be used to learn about the biological response before and after treatment.

Ovarian Cancer

M.D. Anderson Cancer Center18 participantsStarted Dec 2004

Houston, Texas, United States

COMPLETEDPhase 2

BIBF 1120 in Bevacizumab Resistant, Persistent, or Recurrent Epithelial Ovarian Cancer

NCT01669798

The main purpose of this study is to see if BIBF 1120 can increase the number of women with bevacizumab resistant, persistent, or recurrent epithelial ovarian cancer who do not progress for at least six months.

Ovarian CancerFallopian Tube CancerPeritoneal Cancer

AA Secord32 participantsStarted Feb 2013

Durham, North Carolina, United States • Charlottesville, Virginia, United States • Norfolk, Virginia, United States

Non-coding RNA in the Exosome of the Epithelia Ovarian Cancer

Intraperitoneal tgDCC-E1 and Intravenous Paclitaxel in Women With Platinum-Resistant Ovarian Cancer

BIBF 1120 in Bevacizumab Resistant, Persistent, or Recurrent Epithelial Ovarian Cancer

Related Searches

Phase II Study of NGR-hTNF in Combination With Doxorubicin in Platinum-resistant Ovarian Cancer

ILX-295501 in Treating Patients With Stage III or Stage IV Ovarian Cancer That Has Not Responded to Previous Treatment

A Phase II, Open-Label Study Evaluating the Effect Of GW786034 In Subjects With Ovarian Cancer

Fallopian Tube Removal as a Method of Ovarian Cancer Prevention: A Descriptive Study

Trial of Inquiry Based Stress Reduction (IBSR) Program for BRCA1/2 Mutation Carriers

Sunitinib in Recurrent and Refractory Ovarian, Fallopian Tube and Peritoneal Carcinoma

Secondary Debulking Surgery +/- Hyperthermic Intraperitoneal Chemotherapy in Stage III Ovarian Cancer

Hyperthermic Intraperitoneal Chemotherapy With Paclitaxel in Advanced Ovarian Cancer

Phase II Study DCVAC/OvCa Plus Carboplatin Gemcitabine Relapsed Platinum (Pt)-Sensitive Epithelial Ovarian Carcinoma

Improving Employment in Patients Who Have Survived Cervical Cancer, Uterine Cancer, or Ovarian Cancer

Upfront Treatment With Chemotherapy and Bevacizumab in Advanced Ovarian Cancer

M. D. Anderson Symptom Inventory - Ovarian Cancer

Intervention of Ovarian Cancer With Antigen-specific Engineered Immune Effectors

Docetaxel and PTK787 in Metastatic Breast Cancer Patients and Gynecological Cancer Patients

Avastin +/- Erlotinib Consolidation Chemotherapy After Carboplatin, Paclitaxel, and Avastin (CTA) Induction Therapy for Advanced Ovarian, Fallopian Tube, Primary Peritoneal Cancer & Papillary Serous or Clear Cell Mullerian Tumors

Open Trial of Bendamustine Hydrochloride in Women With Advanced Ovarian Cancer

Sunitinib® in Patients With Recurrent Ovarian Clear Cell Carcinoma